Relapsing-Remitting Multiple Sclerosis Market size was valued at USD 4.5 billion in 2024 and is likely to cross USD 6.69 billion by 2037, registering more than 3.1% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of relapsing-remitting multiple sclerosis is estimated at USD 4.62 billion.
One of the key factors contributing to the growth of the market is the rising prevalence of relapsing-remitting multiple sclerosis (RRMS). With the growing prevalence of the disease, the demand for advanced treatment has increased significantly, which is one of the crucial factors accelerating the market growth. According to the National Multiple Sclerosis Society (NMSS), RRMS is the most common form of multiple sclerosis, and nearly 85% of people with multiple sclerosis are initially diagnosed with this form. Additionally, the growing geriatric population across the world is also anticipated to fuel the growth of the relapsing-remitting multiple sclerosis market in the upcoming years. The world's older population continues to rise at an alarming rate. Globally, the risk of multiple sclerosis is increasing in older people, which is further expected to generate substantial demand for the product. According to the World Bank Data, an estimated 9.099% of the world's total population was 65 years and older in 2019. Further, as notified by the World Population Prospects, it is estimated that 1 in every 6 people globally will be over 65 years of age by 2050. Besides, it was also estimated that by 2020, the number of people belonging to the age group 60 and older would outnumber the population of children younger than 5 years. In addition to this, the world population of 80 years and older is also projected to grow from 143 million in 2019 to approximately 426 million in 2050.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
3.1% |
|
Base Year Market Size (2024) |
USD 4.5 billion |
|
Forecast Year Market Size (2037) |
USD 6.69 billion |
|
Regional Scope |
|
The relapsing-remitting multiple sclerosis market is segmented by drug type into beta-interferon, cladribine, dimethyl fumarate, fingolimod, ozanimod, other drugs. The beta-interferon segment is estimated to capture the larger share of the market, in 2021, and is anticipated to grow at a lucrative CAGR during the forecast period. This can be attributed to the product approval by the U.S. Food & Drug Administration (FDA), along with its higher efficiency.
The relapsing-remitting multiple sclerosis market has been segmented into oral, injectable, and intravenous based on the route of administration. Over the next few years, the oral segment is anticipated to grow at a lucrative CAGR on account of the increased efficiency rate of the oral route of administration. Further, the increasing approval of oral drugs is also anticipated to contribute to the market segment's growth. Based on end-user, the hospital segment is expected to capture a higher share in 2020 and is further anticipated to grow at a lucrative rate over the forecast period, which is primarily attributed to the growing influx of patients in hospitals.
Our in-depth analysis of the global relapsing-remitting multiple sclerosis market includes the following segments:
|
Drug Type |
|
|
Route of Administration |
|
|
End-user |
|
Geographically, the relapsing-remitting multiple sclerosis market is segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa region. North America industry is poised to dominate majority revenue share by 2037, attributed to growing prevalence of RRMS in the region. According to the Multiple Sclerosis Association of America (MSAA), an estimated 1 million people in the United States are currently living with multiple sclerosis. In addition, it has been reported that the risk of developing multiple sclerosis in the U.S. is 3.5 in 1,000 people. Moreover, the favourable reimbursement policies in the country are also projected to drive the market’s growth in the forthcoming years. Another factor contributing to the growth of the relapsing-remitting multiple sclerosis market is the rising geriatric population in the region. According to the U.S. Census Bureau, more than 54 million people in the United States are aged 65 years and older. Moreover, it is to be noted that multiple sclerosis is becoming more prevalent in the geriatric population, which is further anticipated to generate a high demand for advanced treatment in the region.
Author Credits: Radhika Pawar
Copyright © 2025 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?